BioInvent International AB (SE:BINV)
:BINV
Want to see SE:BINV full AI Analyst Report?
BINV Stock Chart & Stats
kr30.30
kr0.20(0.78%)
At close: 4:00 PM EST
kr30.30
kr0.20(0.78%)
Day’s Range― - ―
52-Week Rangekr19.22 - kr41.60
Previous CloseN/A
Volume47.26K
Average Volume (3M)91.72K
Market Cap
kr1.69B
Enterprise Valuekr1.46B
Total Cash (Recent Filing)kr456.48M
Total Debt (Recent Filing)kr6.25M
Price to Earnings (P/E)―
Beta0.54
Next Earnings
Aug 27, 2026EPS Estimate
-1.9Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-5.09
Shares Outstanding65,804,360
10 Day Avg. Volume84,851
30 Day Avg. Volume91,723
Financial Highlights & Ratios
PEG Ratio0.26
Price to Book (P/B)3.47
Price to Sales (P/S)8.54
P/FCF Ratio-7.58
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
kr90.00Price Target Upside197.03% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-4.7
Revenue Forecast (FY)kr277.77M
Bulls Say, Bears Say
Bulls Say
Clinical Efficacy — BI-1808 (CTCL)High single-agent response and disease control in a rare T‑cell lymphoma indication, plus orphan designation, creates a durable development advantage: faster regulatory pathways, stronger pricing/market exclusivity potential, and a more compelling partnering asset for long-term value capture.
Clinical Activity — BI-1206 (NHL)Robust response rates across multiple non-Hodgkin lymphoma subtypes validate the mechanism and support both expansion and registration strategies. Such broad activity supports program diversification, multiple potential approval paths, and stronger leverage in partnership or commercialization discussions over the next several years.
Low Leverage / Financial FlexibilityExtremely low debt gives the company structural financial flexibility versus highly leveraged peers, lowering refinancing pressure and enabling strategic choices (partnering, selective asset sales, or focused raises) to fund pivotal programs without immediate solvency risk.
Bears Say
Persistent Cash Burn & Negative Cash FlowSustained large negative operating and free cash flow means the business cannot self-fund development. Over time this forces recurrent capital raises or deal making, dilutes equity, and can compel program prioritization that slows parallel development, limiting long-run optionality.
Short Runway / Financing DependenceA one-year financing assessment creates structural execution risk: critical mid‑2026 readouts must deliver or be monetized via partnerships to fund 2027 pivotal plans. This dependency can force hurried or sub‑optimal partnering/financing terms and may delay or downscale programs if outcomes miss expectations.
Revenue Mix Reliant On One-time ItemsReliance on non‑recurring payments and volatile production revenue undermines predictability of operating income. Without recurring commercial revenues, cash modeling and long-term funding projections remain heavily milestone-dependent, increasing financing uncertainty through clinical cycles.
BioInvent International AB News
BINV FAQ
What was BioInvent International AB’s price range in the past 12 months?
BioInvent International AB lowest stock price was kr19.22 and its highest was kr41.60 in the past 12 months.
What is BioInvent International AB’s market cap?
BioInvent International AB’s market cap is kr1.69B.
When is BioInvent International AB’s upcoming earnings report date?
BioInvent International AB’s upcoming earnings report date is Aug 27, 2026 which is in 96 days.
How were BioInvent International AB’s earnings last quarter?
BioInvent International AB released its earnings results on Apr 29, 2026. The company reported -kr1.903 earnings per share for the quarter, the consensus estimate of -kr1.903 by kr0.
Is BioInvent International AB overvalued?
According to Wall Street analysts BioInvent International AB’s price is currently Undervalued.
Does BioInvent International AB pay dividends?
BioInvent International AB does not currently pay dividends.
What is BioInvent International AB’s EPS estimate?
BioInvent International AB’s EPS estimate is -1.9.
How many shares outstanding does BioInvent International AB have?
BioInvent International AB has 65,804,360 shares outstanding.
What happened to BioInvent International AB’s price movement after its last earnings report?
BioInvent International AB reported an EPS of -kr1.903 in its last earnings report, expectations of -kr1.903. Following the earnings report the stock price went up 3.944%.
Which hedge fund is a major shareholder of BioInvent International AB?
Currently, no hedge funds are holding shares in SE:BINV
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
BioInvent International AB
BioInvent International AB (publ), a clinical-stage company, discovers, researches, and develops immuno-modulatory antibodies for the treatment of cancer in Sweden, Europe, the United States, Japan, and internationally. Its lead drug candidate is BI-1206 for the treatment of non-Hodgkin lymphoma and solid tumors. The company also develops tumor associated myeloid cells; cancer-associated regulatory T cells, which modulate the immune system; BT-001 in solid tumors; and BI-1808 and BI-1910, which are anti-TNFR2 antibodies for the treatment of solid tumors and cutaneous T-cell lymphoma. It has a strategic collaboration with Pfizer Inc. for the development of antibodies against tumor-associated myeloid cells; partnership and collaboration with Transgene to co-develskylinop multi-functional oncolytic viruses for treatment of solid tumors; and collaboration and supply agreement with Merck for the clinical development of BI-1808. The Company was incorporated in 1996 and is based in Lund, Sweden.
BINV Company Deck
BINV Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presents multiple strong clinical data points (notably BI-1808 in ovarian cancer and CTCL, and BI-1206 in NHL) with supportive safety and clear near-term catalysts and collaborations with Merck and AstraZeneca. Financially, Q4 sales fell sharply due to lower contract production while full-year sales increased materially driven by one-time items; operating costs and losses rose and the company states it is financed for only the next 12 months, meaning further financing or partnering will be needed to sustain a larger pivotal development plan. Overall, the positive clinical momentum and strategic partnerships outweigh short-term financial and execution risks, but upcoming readouts will be critical for de-risking future funding and pivotal starts.View all SE:BINV earnings summariesBINV Stock 12 Month Forecast
Average Price Target
kr90.00
▲(197.03% Upside)
Technical Analysis
Hansa Biopharma AB
―
Saniona AB
―
Vicore Pharma Holding AB
―
Xspray Pharma AB
―
Cantargia AB
―
Options Prices
Currently, No data available
---